sLEP-R ELISA is for the quantitative determination of human soluble leptin receptor (sLEP-R), product number R07.
The adipokine leptin realizes signal transduction via four different leptin receptor (LEP-R) isoforms. However, the amount of functionally active LEP-R is influenced by constitutive cleavage of the extracellular domain. The product of the cleavage process, called soluble leptin receptor (sLEP-R), is the major binding protein for leptin in human blood and modulates its bioavailability. Concentrations of sLEP-R are differentially regulated in metabolic disorders, such as type 1 diabetes mellitus or obesity, and may therefore increase or decrease leptin sensitivity. Lipotoxicity and apoptosis increase LEP-R cleavage via ADAM10-dependent mechanisms. In contrast, although increased levels of sLEP-R appear to directly inhibit leptin effects, reduced levels of sLEP-R may reflect decreased membrane expression of LEP-R. These results explain, in part, changes in leptin sensitivity that are related to changes in serum sLEP-R concentrations observed in metabolic disorders.
| sLEP-R ELISA | Soluble Leptin Receptor ELISA |
| Product number | R07 |
| regulatory status (EU) | RUO |
| Calibration | Recombinant eukaryotically expressed soluble leptin receptor. |
| Incubation period | 5 h |
| Antibody | Specific high-affinity antibodies |
| Standard | 8 individual standards, 0-30 ng/mL |
| Assay Range [µg/L] | 0,0385-150 |
| Sample matrix | Serum / Plasma |
| Sample dilution | 1:5 |
| analyt. Sensitivity [µg/L] | 0,0385 |
| Intra-/Interassay Variance [%] | < 10% |
| Package insert |  |
Englisch 
German